A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria

Mayo Clinic Proceedings

Volumn 87, Issue 9, 2012, Pages 835-842

  Karnes, R Jeffrey ^a   Fernandez, Cecilia A ^b   Shuber, Anthony P ^b  

^a MAYO CLINIC   (United States)

^b Predictive Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A;

AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CYSTOSCOPY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; FEMALE; FGFR3 GENE; GENE; GENE IDENTIFICATION; HEMATURIA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUTANT; NID2 GENE; NON INVASIVE PROCEDURE; OBSERVATIONAL STUDY; PREDICTION; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TWIST1 GENE; URINALYSIS; UROGENITAL TRACT CANCER;

EID: 84866362615     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.04.013     Document Type: Article

References (26)

1. Nieder AM, Lotan Y, Nuss GR, et al. Are patients with hematuria appropriately referred to urology? a multi-institutional questionnaire based survey. Urol Oncol. 2010;28(5):500-503.
2. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000;163(2):524-527. (Pubitemid 30060509)
3. Johnson EK, Daignault S, Zhang Y, Lee CT. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008;72(3):498-502.
4. Elias K, Svatek RS, Gupta S, Ho R, Lotan Y. High-risk patients with hematuria are not evaluated according to guideline recommendations. Cancer. 2010;116(12):2954-2959.
5. Cohen RA, Brown RS. Clinical practice: microscopic hematuria. N Engl J Med. 2003;348(23):2330-2338.
6. Singh R, Saleemi A, Walsh K, Popert R, O'Brien T. Near misses in bladder cancer: an airline safety approach to urology. Ann R Coll Surg Engl. 2003;85(6):378-381. (Pubitemid 37390937)
7. Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screen-ing versus those with standard clinical presentations. Urology. 1995;45(3):387-396.
8. Chou R, Dana T. Screening adults for bladder cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153(7):461-468.
9. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005;66(6, suppl 1):35-63. (Pubitemid 43049608)
10. Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011;186(6):2158-2167.
11. Wild PJ, Fuchs T, Stoehr R, et al. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1798-1806.
12. McDonald MM, Swagerty D, Wetzel L. Assessment of microscopic hematuria in adults. Am Fam Physician. 2006;73(10): 1748-1754.
13. Moyer VA. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;155(4):246-251.
14. Fernandez CA, Wszolek MF, Loughlin KR, Libertino JA, Summerhayes IC, Shuber AP. A novel approach to using matrix metalloproteinases for bladder cancer. J Urol. 2009;182(5): 2188-2194.
15. Hong YM, Loughlin KR. Economic impact of tumor markers in bladder cancer surveillance. Urology. 2008;71(1):131-135. (Pubitemid 351173253)
16. Duggan B, Williamson K. Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol. 2004; 14(5):277-286. (Pubitemid 39141984)
17. van Oers JM, Lurkin I, van Exsel AJ, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005;11(21):7743-7748. (Pubitemid 41611617)
18. Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade nonmuscle-invasive bladder cancer. Clin Cancer Res. 2010;16(11): 3011-3018.
19. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001;61(4):1265-1268. (Pubitemid 34292538)
20. van Oers JM, Zwarthoff EC, Rehman I, et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650-657.
21. Kompier LC, van der Aa MN, Lurkin I, et al. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol. 2009; 218(1):104-112.
22. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107(9):2173-2179. (Pubitemid 44665651)
23. Madeb R, Golijanin D, Knopf J, et al. Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology. 2010;75(1):20-25.
24. Tilki D, Burger M, Dalbagni G, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2011;60(3):484-492.
25. Mohr DN, Offord KP, Owen RA, Melton LJ III. Asymptomatic microhematuria and urologic disease: a population-based study. JAMA. 1986;256(2):224-229. (Pubitemid 16097834)
26. Feifer AH, Steinberg J, Tanguay S, Aprikian AG, Brimo F, Kassouf W. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. Urology. 2010;75(6):1278-1282.